Biovica International

Growing Cancer Incidence And AI Will Drive Diagnostic Expansion

AnalystHighTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

18 Aug 25

Updated

18 Aug 25

AnalystHighTarget's Fair Value

SEK 3.00

78.5% undervalued

18 Aug

SEK 0.65

-76.8%

2.9%

Author's Valuation

SEK 3.0

78.5% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

SEK 3.0

78.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

72.19%

Biotech revenue growth rate

12.71%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.92%

Calculation

SEK 26.97m

Earnings '28

15.93x

PE Ratio '28

SEK 429.60m

Market Cap '28

SEK 429.60m

Market Cap '28

123.99m

No. shares '28

SEK 3.46

Share Price '28

SEK 3.46 Share Price '28

Discounted to 2025 @ 4.92% p.a.

SEK 3.00

Fair Value '25